While this improved prognostic accuracy for oligodendrogliomas and gliomas now known as grade 4 IDH-mutant astrocytomas, clinical outcomes for grade 2 and 3 IDH-mutant diffuse astrocytomas remained heterogenous [53,63,68,69]. This evidence concerns the gene IDH1 and central nervous system cancer.